Active vitamin d treatment in ckd patients raises serum sclerostin and this effect is modified by circulating pentosidine levels

1,25(OH)2Vitamin D increases the expression of sclerostin gene. Whether vitamin D receptor activation (VDRA) influences serum sclerostin in CKD and whether compounds interfering with VDRA like Advanced Glycosylation End Products (AGEs) may alter the sclerostin response to VDRA is unknown.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - Category: Nutrition Authors: Source Type: research